Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 2Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × budigalimab × Gastrointestinal × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

AbbVie

Phase 2 Active not recruiting
130 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡